SION

Sionna Therapeutics, Inc.

Price Chart

Latest Quote

$5.90

+0.03 (+0.51%)

Current Price

Previous Close	$5.87
Open	$5.87
Day High	$5.95
Day Low	$5.75
Volume	299,656

Fetched: 2026-08-31T17:19:40

Stock Information

Shares Outstanding	45.15M
Total Debt	$8.07M
Cash Equivalents	$211.03M
Net Income	$-97.38M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$272.26M
EPS (TTM)	$-2.15
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$69.67M
Income	$-97.38M
Book/sh	$5.88
Cash/sh	$4.67
Employees	59

Financial Ratios

Quick Ratio	19.57
Current Ratio	20.05
Debt/Eq	3.04

Returns & Margins

ROA	-21.54%
ROE	-32.34%

Ownership

Insider Ownership	6.84%
Institutional Ownership	107.19%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.38
P/B	1.02

Analyst Data

Recommendation	none
Target Price	$15.17

Technical Indicators

SMA20	$14.58
SMA50	$32.49
SMA200	$37.74
RSI	59.55
ATR	0.5604

Shares Float	17.03M
Short Float	15.24%
Short Ratio	1.22
Rel Volume	0.30

Performance History

Week	+7.87%
Month	-87.21%
Quarter	-85.26%
6 Months	-82.22%
YTD	-84.62%
Year	-76.56%
10 Years	-75.88%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-08-31	$6.03	1,381,155
2026-08-28	$5.87	783,100
2026-08-27	$6.06	773,900
2026-08-26	$6.17	923,800
2026-08-25	$6.25	1,973,200
2026-08-24	$5.59	1,773,800
2026-08-21	$5.29	1,937,800
2026-08-20	$5.52	1,749,500
2026-08-19	$6.25	1,873,700
2026-08-18	$5.94	2,057,600
2026-08-17	$5.91	2,985,500
2026-08-14	$6.46	2,877,400
2026-08-13	$6.54	5,485,900
2026-08-12	$6.25	9,438,000
2026-08-11	$5.10	14,931,100
2026-08-10	$4.50	38,644,400
2026-08-07	$51.04	747,500
2026-08-06	$49.61	778,300
2026-08-05	$47.34	757,700
2026-08-04	$49.94	913,100
2026-08-03	$49.26	509,000

About Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

📰 Latest News

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

Motley Fool • 2026-08-20T19:50:00Z

Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?

Simply Wall St. • 2026-08-13T09:11:03Z

Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?

Simply Wall St. • 2026-08-13T05:13:01Z

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

MT Newswires • 2026-08-12T15:02:52Z

Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall

Simply Wall St. • 2026-08-12T10:12:15Z

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses

Insider Monkey • 2026-08-12T03:41:31Z

Sionna Therapeutics stock falls 92% after SION-719 trial failure

Quartz • 2026-08-11T13:11:57Z

Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure

Simply Wall St. • 2026-08-11T08:12:14Z

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path

MarketBeat • 2026-08-11T04:03:13Z

Immunic appoints Elena Ridloff to board of directors

Proactive • 2026-08-10T20:36:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$88,982,000	$70,556,000	$50,333,000	$41,372,000
Other Income Expense	$419,000	$698,000	$301,000	-
Other Non Operating Income Expenses	$419,000	$698,000	$301,000	-
Net Non Operating Interest Income Expense	$13,295,000	$8,170,000	$2,769,000	$1,132,000
Operating Expense	$88,982,000	$70,556,000	$50,333,000	$41,372,000
General And Administrative Expense	$28,719,000	$13,268,000	$9,707,000	$6,767,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000
Net Interest Income	$13,295,000	$8,170,000	$2,769,000	$1,132,000
Interest Income	$13,295,000	$8,170,000	$2,769,000	$1,132,000
Normalized Income	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000
Net Income From Continuing And Discontinued Operation	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000
Total Operating Income As Reported	$-88,982,000	$-70,556,000	$-50,333,000	$-41,372,000
Net Income Common Stockholders	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000
Net Income	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000
Net Income Including Noncontrolling Interests	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000
Net Income Continuous Operations	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000
Pretax Income	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000
Interest Income Non Operating	$13,295,000	$8,170,000	$2,769,000	$1,132,000
Operating Income	$-88,982,000	$-70,556,000	$-50,333,000	$-41,372,000
Per Share
Diluted EPS	$-1.88	$-1.45	$-1.70	$-2.32
Basic EPS	$-1.88	$-1.45	$-1.70	$-2.32
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-88,335,000	$-69,888,000	$-49,750,000	$-41,250,000
Reconciled Depreciation	$647,000	$668,000	$583,000	$122,000
EBITDA (Bullshit earnings)	$-88,335,000	$-69,888,000	$-49,750,000	$-41,250,000
EBIT	$-88,982,000	$-70,556,000	$-50,333,000	$-41,372,000
Diluted Average Shares	$39,962,163	$42,444,742	$27,797,075	$17,332,468
Basic Average Shares	$39,962,163	$42,444,742	$27,797,075	$17,332,468
Diluted NI Availto Com Stockholders	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000
Research And Development	$60,263,000	$57,288,000	$40,626,000	$34,605,000
Selling General And Administration	$28,719,000	$13,268,000	$9,707,000	$6,767,000
Other Gand A	$9,821,000	$5,426,000	$3,783,000	$2,283,000
Salaries And Wages	$18,898,000	$7,842,000	$5,924,000	$4,484,000

Fetched: 2026-08-29

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$306,833,000	$-163,713,000	$-114,881,000	$-69,924,000
Total Assets	$325,953,000	$185,752,000	$51,945,000	$87,369,000
Total Non Current Assets	$84,534,000	$34,759,000	$12,738,000	$3,536,000
Other Non Current Assets	$963,000	$3,956,000	$1,006,000	$962,000
Investmentin Financial Assets	$74,420,000	$20,505,000	$0	-
Current Assets	$241,419,000	$150,993,000	$39,207,000	$83,833,000
Other Current Assets	$5,537,000	$3,455,000	$686,000	$1,223,000
Cash Cash Equivalents And Short Term Investments	$235,882,000	$147,538,000	$38,521,000	$82,610,000
Cash And Cash Equivalents	$58,451,000	$37,788,000	$38,521,000	$54,837,000
Debt
Total Debt	$8,677,000	$9,749,000	$10,477,000	$0
Long Term Debt And Capital Lease Obligation	$7,408,000	$8,677,000	$9,749,000	$0
Current Debt And Capital Lease Obligation	$1,269,000	$1,072,000	$728,000	-
Liabilities
Total Liabilities Net Minority Interest	$19,120,000	$349,465,000	$166,826,000	$157,293,000
Total Non Current Liabilities Net Minority Interest	$7,408,000	$339,045,000	$158,789,000	$149,040,000
Current Liabilities	$11,712,000	$10,420,000	$8,037,000	$8,253,000
Other Current Liabilities	$6,000	-	-	-
Payables And Accrued Expenses	$5,697,000	$6,376,000	$4,197,000	$6,300,000
Payables	$769,000	$1,186,000	$719,000	$557,000
Accounts Payable	$769,000	$1,186,000	$719,000	$557,000
Equity
Common Stock Equity	$306,833,000	$-163,713,000	$-114,881,000	$-69,924,000
Total Equity Gross Minority Interest	$306,833,000	$-163,713,000	$-114,881,000	$-69,924,000
Stockholders Equity	$306,833,000	$-163,713,000	$-114,881,000	$-69,924,000
Gains Losses Not Affecting Retained Earnings	$540,000	$368,000	$0	$-16,000
Other Equity Adjustments	$540,000	$368,000	-	$-16,000
Retained Earnings	$-256,354,000	$-181,086,000	$-119,398,000	$-72,135,000
Preferred Securities Outside Stock Equity	$0	$330,368,000	$149,040,000	$149,040,000
Preferred Stock Equity	-	$330,368,000	$149,040,000	$149,040,000
Other
Ordinary Shares Number	$44,723,585	$42,444,742	$42,444,742	$42,444,742
Share Issued	$44,723,585	$42,444,742	$42,444,742	$42,444,742
Tangible Book Value	$306,833,000	$-163,713,000	$-114,881,000	$-69,924,000
Invested Capital	$306,833,000	$-163,713,000	$-114,881,000	$-69,924,000
Working Capital	$229,707,000	$140,573,000	$31,170,000	$75,580,000
Capital Lease Obligations	$8,677,000	$9,749,000	$10,477,000	$0
Total Capitalization	$306,833,000	$-163,713,000	$-114,881,000	$-69,924,000
Additional Paid In Capital	$562,602,000	$17,000,000	$4,515,000	$2,225,000
Capital Stock	$45,000	$5,000	$2,000	$2,000
Common Stock	$45,000	$5,000	$2,000	$2,000
Preferred Stock	$0	$0	$149,040,000	$149,040,000
Long Term Capital Lease Obligation	$7,408,000	$8,677,000	$9,749,000	$0
Current Capital Lease Obligation	$1,269,000	$1,072,000	$728,000	$0
Pensionand Other Post Retirement Benefit Plans Current	$4,740,000	$2,972,000	$3,112,000	$1,953,000
Current Accrued Expenses	$4,928,000	$5,190,000	$3,478,000	$5,743,000
Investments And Advances	$74,420,000	$20,505,000	$0	-
Available For Sale Securities	$74,420,000	$20,505,000	-	-
Net PPE	$9,151,000	$10,298,000	$11,732,000	$2,574,000
Accumulated Depreciation	$-2,122,000	$-1,571,000	$-914,000	$-344,000
Gross PPE	$11,273,000	$11,869,000	$12,646,000	$2,918,000
Leases	$1,920,000	$1,854,000	$1,854,000	$0
Other Properties	$8,501,000	$9,293,000	$9,954,000	$617,000
Machinery Furniture Equipment	$852,000	$722,000	$722,000	$0
Properties	$0	$0	$0	$0
Other Short Term Investments	$177,431,000	$109,750,000	$0	$27,773,000
Construction In Progress	-	$0	$116,000	$2,301,000

Fetched: 2026-08-29

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-66,674,000	$-52,814,000	$-44,815,000	$-37,942,000
Operating Activities
Operating Cash Flow	$-66,297,000	$-52,787,000	$-43,699,000	$-36,068,000
Cash Flow From Continuing Operating Activities	$-66,297,000	$-52,787,000	$-43,699,000	$-36,068,000
Investing Activities
Capital Expenditure	$-377,000	$-27,000	$-1,116,000	$-1,874,000
Investing Cash Flow	$-118,749,000	$-126,913,000	$27,352,000	$-29,263,000
Cash Flow From Continuing Investing Activities	$-118,749,000	$-126,913,000	$27,352,000	$-29,263,000
Financing Activities
Issuance Of Capital Stock	$202,071,000	$181,328,000	$0	$110,791,000
Financing Cash Flow	$205,710,000	$178,967,000	$31,000	$110,855,000
Cash Flow From Continuing Financing Activities	$205,710,000	$178,967,000	$31,000	$110,855,000
Net Preferred Stock Issuance	$0	$181,328,000	$0	$110,791,000
Preferred Stock Issuance	$0	$181,328,000	$0	$110,791,000
Net Common Stock Issuance	$202,071,000	$0	-	-
Common Stock Issuance	$202,071,000	$0	-	-
Net Other Financing Charges	-	$-2,502,000	-	-
Other
End Cash Position	$59,414,000	$38,750,000	$39,483,000	$55,799,000
Beginning Cash Position	$38,750,000	$39,483,000	$55,799,000	$10,275,000
Changes In Cash	$20,664,000	$-733,000	$-16,316,000	$45,524,000
Proceeds From Stock Option Exercised	$3,639,000	$141,000	$31,000	$64,000
Net Investment Purchase And Sale	$-118,372,000	$-126,886,000	$28,468,000	$-27,389,000
Sale Of Investment	$206,653,000	$55,955,000	$52,000,000	$13,000,000
Purchase Of Investment	$-325,025,000	$-182,841,000	$-23,532,000	$-40,389,000
Net PPE Purchase And Sale	$-377,000	$-27,000	$-1,116,000	$-1,874,000
Purchase Of PPE	$-377,000	$-27,000	$-1,116,000	$-1,874,000
Change In Working Capital	$-2,652,000	$-3,075,000	$-783,000	$2,764,000
Change In Other Current Liabilities	$-2,128,000	$-1,897,000	$-172,000	$0
Change In Other Current Assets	$0	$35,000	$0	-
Change In Payables And Accrued Expense	$1,558,000	$1,547,000	$-944,000	$3,517,000
Change In Accrued Expense	$1,975,000	$1,080,000	$-1,106,000	$5,031,000
Change In Payable	$-417,000	$467,000	$162,000	$-1,514,000
Change In Account Payable	$-417,000	$467,000	$162,000	$-1,514,000
Change In Prepaid Assets	$-2,082,000	$-2,760,000	$333,000	$-753,000
Other Non Cash Items	$1,962,000	$10,601,000	$2,184,000	-
Stock Based Compensation	$12,066,000	$3,708,000	$2,259,000	$1,686,000
Amortization Of Securities	$-3,052,000	$-3,001,000	$-679,000	$-400,000
Depreciation Amortization Depletion	$647,000	$668,000	$583,000	$122,000
Depreciation And Amortization	$647,000	$668,000	$583,000	$122,000
Depreciation	$647,000	$668,000	$583,000	$122,000
Net Income From Continuing Operations	$-75,268,000	$-61,688,000	$-47,263,000	$-40,240,000

Fetched: 2026-08-29